Q-omics provides the consensus-scored CRYBB3 profile across patient tissues and cancer cell-line models. CRYBB3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CRYBB3 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, CRYBB3 RNA expression shows 13,941 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where CRYBB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYBB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYBB3 survival associations across molecular data types. CRYBB3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYBB3 RNA expression–survival associations across cancer types. High CRYBB3 expression shows unfavorable associations in ACC, COAD and UVM, but favorable associations in BLCA, HNSC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CRYBB3 RNA expression.
This table summarizes CRYBB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CRYBB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYBB3 shows lower tumor expression in KIRP, THCA and KICH and higher tumor expression in HNSC, STAD and LUSC. The KIRP box plot shows higher CRYBB3 RNA expression in normal versus tumor tissue (log2 FC = −1.468, t-test p < 0.001).
This table shows molecular features associated with CRYBB3 in patient tissues and cancer cell lines. In patient samples, CRYBB3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYBB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
